(E)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one oxime

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (E)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one oxime
• 英文别名: (NZ)-N-(6-methoxy-3,4-dihydro-2H-naphthalen-1-ylidene)hydroxylamine
• 化学式: C₁₁H₁₃NO₂
• mdl: MFCD00859993
• 分子量: 191.23
• InChiKey: QEPLWBMPKVIAOH-QXMHVHEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TRICYCLIC HETEROCYCLIC COMPOUNDS
  申请人：Dhar T.G. Murali

  公开号：US20120214767A1

  公开（公告）日：2012-08-23

  Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X 1 , X 2 , X 3 , W, Q 1 , Q 2 , and G 2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）的化合物或其立体异构体或盐，其中：X1、X2、X3、W、Q1、Q2和G2在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面有用，例如自身免疫性疾病和血管疾病。
• PREPARATION OF CHIRAL AMIDES AND AMINES
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20140057990A1

  公开（公告）日：2014-02-27

  This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.

  本发明提供了一种将肟转化为烯酰胺的便捷方法。该过程不需要使用金属试剂。因此，它可以生产所需的化合物，而不会产生大量的金属废物。烯酰胺是制备酰胺和胺的有用前体。本发明提供了一种将原生手性烯酰胺转化为相应手性酰胺的方法。在一个示例过程中，通过使用手性氢化催化剂，在氢化过程中引入手性氨基中心。在选定的实施例中，本发明提供了制备酰胺和胺的方法，其中包括1,2,3,4-四氢-N-烷基-1-萘胺或1,2,3,4-四氢-1-萘胺亚结构。
• Tricyclic heterocyclic compounds
  申请人：Bristol-Myers Squibb Company

  公开号：EP2592071A1

  公开（公告）日：2013-05-15

  Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了式 (I) 的化合物 或其立体异构体或盐，其中X1、X2、X3、W、Q1、Q2 和 G2 在本文中定义。还公开了将此类化合物用作 G 蛋白偶联受体 S1P1 选择性激动剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓各种治疗领域的疾病或失调，如自身免疫性疾病和血管疾病。
• Chiral amines
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：EP2816024B1

  公开（公告）日：2017-08-02
• US9216972B2
  申请人：——

  公开号：US9216972B2

  公开（公告）日：2015-12-22